CAT and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, we provide evidence that the peroxiredoxin protein may not play an essential role in determining the cellular susceptibility to As2O3, while targeting catalase may greatly enhance the efficacy of As2O3 in CML therapy.